mor

Dermorphin is agonist of μ-opioid receptor (MOR) agonist.

Dermorphin TFA is a new class of opioids-like peptides

MOR modulator-1 (compound 6) is a potent and selective modulator of the μ opioid receptor (MOR). Compared to NAT (6α-configuration), MOR modulator-1 demonstrates improved opioid receptor selectivity, enhanced antagonistic effects in vivo, and overall reduced withdrawal symptoms. It connects to the μ, δ, and γ receptors with carboxamide linkers, showing Ki values of 0.25, 41.1, and 1.30 nM respectively.

MOR agonist-5 is a selective and potent μ-opioid receptor (MOR) agonist with an EC50 of 0.25 nM. It exhibits an EC50 of 10 nM at δ-opioid receptors (DOR), while its EC50 at κ-opioid receptors (KOR) and nociceptin receptors (NOR) is greater than 10000 nM. MOR agonist-5 demonstrates significant antinociceptive activity and is useful for pain-related research.

(Mor-Cor) Ag (III) is a silver (III) corrole complex capable of crossing the blood-brain barrier. It has the ability to scavenge reactive oxygen species induced by Aβ42, disrupt Aβ42 aggregation, and thus alleviate Aβ42-induced neuronal hyperactivity. (Mor-Cor) Ag (III) can be utilized in Alzheimer's disease research.

MOR antagonist 2 hydrochloride is a μ-opioid receptor (MOR) antagonist that can cross the blood-brain barrier. It exhibits an IC50 of 28.37 nM, an EC50 of 4.25 nM, and a Ki of 0.18 nM at MOR. This compound stabilizes the inactive conformation of MOR, thereby reducing receptor activation levels. In mice, MOR antagonist 2 hydrochloride counteracts analgesic effects in the warm-water tail-flick test and induces fewer opioid withdrawal symptoms, such as wet-dog shakes and paw tremors. It is applicable in researching opioid use disorder.

Compound 114 (D3R/MOR antagonist 1) exhibits dual antagonistic activity at dopamine D3 receptors (D3R) and mu-opioid receptors (MOR), with K i values of 46.5 nM and 691 nM, respectively. It offers analgesic benefits through partial agonism at MOR and may decrease the risk of opioid misuse through its D3R antagonistic properties [1].

Compound 121, a D3R/MOR antagonist with K i values of 361 nM and 85.2 nM for D3R and MOR respectively, has the potential for analgesic effects through MOR partial agonism and may reduce opioid-misuse liability through D3R antagonism [1].

Compound 46, designated as MOR agonist-2, serves as a D3R antagonist and a MOR agonist with respective K i values of 7.26 nM and 564 nM. This compound holds potential for analgesic effects attributed to its partial agonism at MOR and may decrease opioid misuse liability owing to its antagonistic action at D3R [1].

MOR agonist-3 (Compound 84) is a dual D3R/MOR antagonist with Ki values of 382 nM and 55.2 nM, respectively. It shows promise for analgesia via partial agonism at MORs and may mitigate opioid abuse via D3R antagonism. This compound is utilized in research pertaining to inflammation and neuropathic pain [1].

Anti-PDGFB Antibody (MOR-8457) is a specialized CHO-expressed fully human IgG1/λ monoclonal antibody target the human platelet-derived growth factor subunit B, inhibition of ligand-receptor engagement with picomolar affinity across various preclinical experimental models to modulate vascular maturation.

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. It works by specifically binding to IL-17C, thereby inhibiting the NF-κB signaling pathway, with an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. MOR-106 effectively reduces skin inflammation and related inflammatory factors in animal models of psoriasis and atopic dermatitis.

N-Methylmoranoline is an inhibitor of α-glucosidase.

MOR agonist-4 (2d), having an EC50 of 11 nM, is a G protein-biased agonist of the Kappa opioid receptor (KOR). This compound features a triazole-based, electron-withdrawing CF3 group and a bias factor of 38. MOR agonist-4 is utilized for antipruritic and analgesic applications.

MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. It is applicable in the study of both acute and chronic inflammation, such as in cases of burns.

Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody specifically targeting MST1R.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF). Otilimab has anti-inflammatory activity, regulates the biological function of GM-CSF by blocking the interaction between GM-CSF and its cell surface receptors, and can be used in studies to treat severe COVID-19 pneumonia.

Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.

Dorsomorphin (BML-275) is an AMPK inhibitor (Ki=109 nM) that is selective and ATP-competitive. Dorsomorphin inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy, and possesses antitumor activity.

Antitumor agent-19 is a modulator of tumor-associated macrophages with EC50s of 17.18 μM and 18.87 μM in the RAW 264.7 cells and the BMDM cells.

Antitumor agent-2 has anti-inflammatory and anti-tumor activity and can be used to study cancer.

Dextrorotation nimorazole phosphate ester TFA is an anti-anaerobic and anti-parasitic agent.

Levorotation nimorazole phosphate ester TFA is an anti-anaerobic and anti-parasitic agent.